AGM Details
The 47th Annual General Meeting will be held on September 18, 2026 at 03:30 PM through Video Conferencing. Key dates include cut-off for voting on September 11, 2026, remote e-voting from September 14-17, 2026, and record date for dividend payment on September 4, 2026.
Financial Performance Highlights (FY 2025-26)
Revenue: ₹2,872.25 million (6.9% growth from ₹2,687.16 million in FY25), primarily from formulations sales in Indian market (99.9% of revenue)
Operating PAT: ₹446 million (19% growth from ₹375 million in FY25)
Operating EBITDA: ₹609 million with 21.2% margin
Profit After Tax: ₹430.82 million (FY25: ₹553.61 million)
Basic EPS: ₹8.26 (₹6.40 in FY25)
Cash & Cash Equivalents: ₹1,907 million including other bank balances of ₹960.78 million
Current Ratio: 5.06
Free Cash Flow: ₹614 million
Exceptional Items
Recognized exceptional expense of ₹20.79 million due to impact of newly notified labor codes on employee benefit computations. Previous year included exceptional gain of ₹196.87 million from disposal of Faridabad factory.
Capital Allocation and Shareholder Returns
Share Buyback: Completed ₹400 million buyback of 1.6 million equity shares at ₹250 per share (40% premium to market price), executed only from public shareholders with 3.67 times subscription.
Dividend: Board recommended final dividend of ₹4.00 per equity share (face value ₹2), representing 200% payout including 75% special dividend. Total expected payout: ₹262 million, subject to shareholder approval.
Total Shareholder Returns: Approximately ₹820 million returned to shareholders over 12 months including FY25 dividend, proposed FY26 dividend, and buyback.
Strategic Acquisition
Acquired 85% equity stake in Aequitas Healthcare Private Limited on July 17, 2026 for ₹208 million (funded through internal accruals). Aequitas generated ₹53 crore revenue in FY26 with relationships across 1,000+ hospitals. Existing promoters retain 15% stake.
Operational Highlights
Therapeutic Focus: Strong presence in gynaecology (ranked 7th), orthopaedics (ranked 2nd), and dermatology (ranked 30th)
Market Reach: 50,000+ doctors, 12,000+ pin codes, 4,000+ towns covered nationwide
Portfolio Strength: 75+ brands with top 10 brands contributing 58% of revenue
Employee Strength: 1,305 employees as of March 31, 2026
Corporate Governance and Compliance
Board Composition: 6 directors including 3 independent directors (2 women independent directors)
Key Appointments: Mr. Anil Kumar Matai as Independent Director, Mr. Nirav Niranjankumar Vora as CFO, Mr. Amrut Medhekar as COO
Auditors: Walker Chandiok & LLP (statutory), Ayush Khandelwal & Associates (secretarial), S S Kothari & Mehta (internal), Kirit Mehta & Co. LLP (cost)
Compliance: Maintained all statutory compliances with material disputed liabilities including VAT (₹57.80 million), Income Tax (₹48.16 million), Custom Duty (₹101.96 million), and GST (₹15.52 million)
ESG and CSR Initiatives
MySakhi Program: Focus on women's health including building 20 pink toilet facilities, menopause awareness webinars, medicine donations worth ₹11.10 lakh, and flood relief in Punjab
CSR Expenditure: ₹2.83 million spent against obligation of ₹7.66 million; balance transferred to unspent CSR account
Forward Outlook
Target of achieving ₹500 crore revenue by FY28 through organic growth initiatives including improved MR productivity, deeper brand building, and focused pipeline of differentiated launches. Will continue to evaluate value-accretive inorganic opportunities.